Minimal residual disease combined with radiological tumor volume as a tool for identification of resected NSCLC patients at high risk of recurrence
INTRODUCTION: Circulating tumor DNA (ctDNA) is a valuable tool for assessing minimal residual disease (MRD) and predicting recurrence in resected non-small cell lung cancer (NSCLC) patients. CONCLUSIONS: MRD detection in NSCLC resected patients predicts relapse and poor outcome; integrating ctDNA with tumor volume enhances identification of high-risk patients.
INTRODUCTION: Circulating tumor DNA (ctDNA) is a valuable tool for assessing minimal residual disease (MRD) and predicting recurrence in resected non-small cell lung cancer (NSCLC) patients. CONCLUSIONS: MRD detection in NSCLC resected patients predicts relapse and poor outcome; integrating ctDNA with tumor volume enhances identification of high-risk patients.
What the study was
- Study design
- Prospective cohort study
- Population
- Patients
- Sample size
- 19
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- The journal of liquid biopsy
Why it surfaced
Matched Early cancer detection; Prospective cohort study; human study; score 7/10 (n=2 r=3 dq=1 pop=1)
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.